Background Identifying biomarkers associated with Alzheimer's disease (AD) progression
may enable patient enrichment and improve clinical trial designs. Epigenome-wide …

Background Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease
impacting an estimated 44 million adults worldwide. The causal pathology of AD …

Background Growing evidence has demonstrated that DNA methylation (DNAm) plays an
important role in Alzheimer's disease (AD) and that DNAm differences can be detected in the …

Introduction This study determined whether blood DNA methylation (DNAm) patterns
differentiate individuals with presymptomatic dementia compared to controls. Methods …

Alzheimer's disease (AD) is a common aging-related neurodegenerative illness. Recently,
many studies have tried to identify AD-or aging-related DNA methylation (DNAm) …

Alzheimer's disease (AD) is characterized by specific alterations of brain DNA methylation
(DNAm) patterns. Age and sex, two major risk factors for AD, are also known to largely affect …

Abstract Background While Alzheimer's disease (AD) remains one of the most challenging
diseases to tackle, genome-wide genetic/epigenetic studies reveal many disease …

To better understand DNA methylation in Alzheimer's disease (AD) from both mechanistic
and biomarker perspectives, we performed an epigenome-wide meta-analysis of blood DNA …

Late-onset Alzheimer's disease (AD) is a complex age-related neurodegenerative disorder
that likely involves epigenetic factors. To better understand the epigenetic state associated …

Abstract Changes in epigenetic marks may help explain the late onset of Alzheimer's
disease (AD). In this study we measured genome-wide DNA methylation by luminometric …